KLH in Clinical Trials

Clinical trials involving KLH. Details such as study status, design and investigators are available by link to outside sites.

Clinical trial links are intended for informational purposes only, and are not solicitations for any study nor provided for the purposes of giving medical advice. See Terms of Use for this site.

(in order by date)

Entries in Adjuvant OPT-821/822 (6)

Thursday
Oct142010

NCT01223235

Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center, Genentech
Phase n/a 

Wednesday
Jun092010

NCT01141491

Friday
May292009

NCT00911560

Thursday
Mar052009

NCT00857545

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Sponsors: Gynecologic Oncology Group, National Cancer Institute (NCI)
Phase II

Friday
Jun062008

NCT00693342

Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Sponsors: Gynecologic Oncology Group, National Cancer Institute (NCI)
Phase III

Tuesday
Jan082008

NCT00597272